Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05320198 · ClinicalTrials.gov registry record · Phase 1
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
A Phase 1 study of Myelodysplastic Syndromes and Anemia, sponsored by Disc Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT05320198: Recruiting Phase 1 study of Myelodysplastic Syndromes and Anemia, sponsored by Disc Medicine.
NCT05320198 is a Phase 1 study of Myelodysplastic Syndromes and Anemia that is actively recruiting participants, run by Disc Medicine. The registered enrollment target is 150 participants, below the 284-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (47% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05320198, a Phase 1 study of Myelodysplastic Syndromes and Anemia, is actively recruiting participants, sponsored by Disc Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis or myelodysplastic syndrome and anemia.
Primary Outcome
Assessed by treatment-emergent adverse events
Conditions Studied
Interventions
- DRUG DISC-0974
Study Locations (20)
Florida
- Mayo Clinic Jacksonville - Jacksonville
- Sylvester Cancer Center - U Miami - Miami
- Moffitt Cancer Center - Tampa
Ohio
- Gabrail Cancer Center Research - Canton
- Cleveland Clinic - Cleveland
- The Ohio State University - Columbus
California
- City of Hope - Duarte - Duarte
- City of Hope - Lennar - Irvine
New York
- Memorial Sloan Kettering Cancer Center - New York
- Icahn School of Medicine at Mount Sinai - New York
Pennsylvania
- Sargon Research - Pennsylvania Cancer Specialists and Research Center - Gettysburg
- University of Pennsylvania - Philadelphia
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Georgia
- Emory Winship Cancer Institute - Atlanta
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2022-06-06 |
| Est. Completion | 2026-09 |
| Phase | Phase 1 |
What NCT05320198 shows while recruiting
NCT05320198 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 284-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (47% lower).
The record links to 7 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 1 intervention - of which DISC-0974 is the first listed.
NCT05320198 names 20 study sites across 13 states, led by Florida, Ohio, California.
Frequently Asked Questions
What is clinical trial NCT05320198 about?
NCT05320198 is a clinical study titled "Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia". This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis or myelodysplastic syndrome and anemia.
What is the current status of trial NCT05320198?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2022-06-06. Estimated completion is 2026-09.
What conditions does trial NCT05320198 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, Anemia, Myelofibrosis, Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis.
What interventions are being tested in trial NCT05320198?
The interventions under investigation include: DISC-0974 (DRUG).
Who is sponsoring clinical trial NCT05320198?
This trial is sponsored by Disc Medicine, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05320198 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05320198's enrollment target sits among peer trials
150 42nd of 173 higher than 132 of 173 other Myelodysplastic Syndromes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelodysplastic Syndromes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
RECRUITING · Phase 1
-
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
RECRUITING · Phase 1
-
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
RECRUITING · Phase 1
-
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
RECRUITING · Phase 1
-
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI